2022
Survival in male breast cancer over the past 3 decades
Leone J, Freedman R, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer Institute 2022, 115: 421-428. PMID: 36583555, PMCID: PMC10086618, DOI: 10.1093/jnci/djac241.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalMale breast cancerOverall survivalBreast cancerMultivariable Cox regressionCancer-specific survivalEnd Results registryYear of diagnosisBreast cancer mortalityStage of diseaseLog-rank testCox regressionCancer mortalityKaplan-MeierIndependent associationCox modelSignificant improvementSignificant associationCancerLife expectancyDiagnosisSurvivalSignificant differencesPatientsMenEstimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool
Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Leone J, Vallejo CT, Winer EP, Lin NU, Tayob N. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool. European Journal Of Cancer 2022, 173: 20-29. PMID: 35841843, DOI: 10.1016/j.ejca.2022.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityHR-positive breast cancerBreast cancerCumulative riskCause mortalityTumor characteristicsRisk of BCSMHormone receptor-positive breast cancerReceptor-positive breast cancerCancer-specific mortalityEnd Results registryLong-term mortalityRisk of deathCancer patient subgroupsPopulation-based riskPathologic variablesInitial diagnosisPatient subgroupsSEER dataPatientsAge groupsCancerMortalityHormone receptorsDiagnosis
2021
Survival in male breast cancer (MaBC) over the past three decades.
Leone J, Freedman R, Leone J, Hassett M, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Survival in male breast cancer (MaBC) over the past three decades. Journal Of Clinical Oncology 2021, 39: 569-569. DOI: 10.1200/jco.2021.39.15_suppl.569.Peer-Reviewed Original ResearchBreast cancer-specific survivalOverall survivalBreast cancerCox modelWorse breast cancer-specific survivalHormone receptor-negative statusGrade 3 diseaseCancer-specific survivalEnd Results registryReceptor-negative statusYear of diagnosisMale breast cancerMultivariate Cox modelDecade of diagnosisPeriod of diagnosisBreast cancer mortalityProportional hazards regressionLog-rank testCause of deathPatient characteristicsMedian ageHazards regressionCancer mortalityKaplan-MeierBlack raceTwenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade
2019
Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.
Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. DOI: 10.1200/jco.2019.37.15_suppl.540.Peer-Reviewed Original ResearchRisk of BCSMBreast cancer-specific mortalityHR- breast cancerBreast cancerAdjusted riskCumulative riskAnnual event rateCancer-specific mortalityHormone receptor statusBreast cancer deathsEnd Results registryBetter adjuvant therapyKaplan-Meier analysisLong-term riskLate deathsAdjuvant therapyLate relapseReceptor statusHR statusPrimary cancerCox regressionBaseline variablesBlack raceCancer deathClinical trials
2008
Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data
Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data. Value In Health 2008, 11: 213-220. PMID: 18380633, DOI: 10.1111/j.1524-4733.2007.00226.x.Peer-Reviewed Original ResearchConceptsBreast cancer recurrenceBreast cancer eventsContralateral breast cancerNonmetastatic breast cancerSEER-Medicare dataBreast cancerCancer recurrenceDistant recurrenceSurveillance EpidemiologyCancer eventsMedicare claimsNational Cancer Institute's Surveillance EpidemiologyBreast cancer leadEnd Results registryTen-year survivalImpact of recurrencePaucity of dataMedian survivalPharmacologic therapyLocal recurrenceRetrospective analysisRecurrencePatientsCancer leadCancer